Lifecore Biomedical (LFCR) to Release Earnings on Thursday

Lifecore Biomedical (NASDAQ:LFCR) is projected to issue its results after the market closes on Thursday, April 2nd. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $25.9570 million for the quarter.

Lifecore Biomedical (NASDAQ:LFCR) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 23.08%.The company had revenue of $35.75 million during the quarter, compared to the consensus estimate of $35.31 million. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Stock Performance

Shares of LFCR opened at $3.87 on Friday. The company has a 50-day simple moving average of $6.95 and a two-hundred day simple moving average of $7.29. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. The firm has a market capitalization of $145.05 million, a PE ratio of -3.95 and a beta of 0.62. Lifecore Biomedical has a one year low of $3.86 and a one year high of $8.98.

Institutional Investors Weigh In On Lifecore Biomedical

Hedge funds and other institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Lifecore Biomedical by 14.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock worth $104,000 after acquiring an additional 1,886 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Lifecore Biomedical by 92.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock valued at $43,000 after acquiring an additional 2,786 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Lifecore Biomedical by 20.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company’s stock valued at $137,000 after purchasing an additional 2,826 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Lifecore Biomedical by 28.4% in the 4th quarter. AQR Capital Management LLC now owns 16,171 shares of the company’s stock worth $132,000 after purchasing an additional 3,574 shares in the last quarter. Finally, Quarry LP bought a new stake in shares of Lifecore Biomedical in the 3rd quarter worth $28,000. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Analysts Set New Price Targets

LFCR has been the subject of several research reports. Zacks Research raised Lifecore Biomedical to a “hold” rating in a research report on Thursday, January 1st. Barrington Research restated an “outperform” rating and set a $5.50 price target on shares of Lifecore Biomedical in a research report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Lifecore Biomedical in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Lifecore Biomedical currently has a consensus rating of “Hold” and a consensus price target of $5.50.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.